Semaglutide is a long-acting synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone responsible for enhancing glucose-dependent insulin secretion. It was developed through amino acid substitutions that significantly improve its resistance to dipeptidyl peptidase-4 (DPP-4) degradation, giving it a prolonged half-life and enabling once-weekly administration in clinical settings.
In scientific research, Semaglutide is studied for its potential to regulate glucose metabolism and body weight through various mechanisms. Upon activation of the GLP-1 receptor, Semaglutide stimulates insulin secretion, inhibits glucagon release, delays gastric emptying, and promotes satiety through central nervous system pathways. These effects make it a valuable compound in research involving energy balance and glycemic control.
One of the distinguishing features of Semaglutide is its ability to cross the blood-brain barrier and act directly on appetite-regulating regions in the hypothalamus. In animal models, this interaction has led to a notable reduction in food intake and an increase in weight loss, independent of caloric intake changes.
Research also suggests that Semaglutide may influence lipid metabolism, inflammatory cytokine expression, and cardiovascular parameters. In models of metabolic dysfunction, the peptide has demonstrated improvements in insulin sensitivity, hepatic steatosis, and systemic inflammation.
Beyond metabolism, Semaglutide is being explored for its neuroprotective properties. Studies are examining its potential to protect neurons from oxidative stress, improve memory function, and influence neuroinflammatory processes. These findings may broaden its application in research on cognitive decline and neurodegenerative disorders.
The compound’s extended half-life and high receptor selectivity make it a preferred choice for studying long-term metabolic adaptations in rodent and primate models. It enables consistent receptor activation over time, which is essential in chronic studies exploring the progression or mitigation of metabolic conditions.
Importantly, all research involving Semaglutide must remain within the bounds of non-clinical use. While promising, its regulatory status restricts use to laboratory environments focused on scientific exploration.
Note: This peptide is not intended for human consumption or clinical use. It is for research purposes only.
Product Data:
- Chemical Name: Semaglutide (GLP-1 Analog)
- CAS Number: 910463-68-2
- Molecular Formula: C187H291N45O59
- Molecular Weight: 4113.58 g/mol
